| Name: | Dexamethasone Sodium Phosphate Diester |
| Catalogue No. | VE006242 |
| CAS No. | N/A |
| Molecular Formula | C44H56F2O12P : Na |
| Molecular Weight | 868.9 |
| Status | In-stock |
| IUPAC Name | Sodium bis(2-((9R,10S,11S,13S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) Phosphate |
| Description | Dexamethasone Sodium Phosphate Diester or Sodium bis(2-((9R,10S,11S,13S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl) Phosphate is a metabolite of Dexamethasone which is evaluated for use in the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies. |
| References | Cázares-Delgadillo, J., et al. “Transdermal Iontophoresis of Dexamethasone Sodium Phosphate in Vitro and in Vivo: Effect of Experimental Parameters and Skin Type on Drug Stability and Transport Kinetics.” European Journal of Pharmaceutics and Biopharmaceutics, vol. 75, no. 2, June 2010, pp. 173–78,https://doi.org/10.1016/j.ejpb.2010.03.011.Richardson, Paul G., et al. “Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma.” New England Journal of Medicine, vol. 352, no. 24, June 20 |
![(16α)-21-[(Ethoxycarbonyl)oxy]-17-hydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione](/public/site/files/site_images/thumb_16alpha-21-ethoxycarbonyl-oxy-17-hydroxy-16-methylpregna-1-4-9-11-triene-3-20-dione47031.png)
